Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria

    ... PNH were either supportive treatment - often including blood transfusion , anti- thrombosis prophylaxis, and sometimes ...

    Research Article last updated 06/07/2016 - 10:56am.

  2. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.

    ... with the aging population. Treatment includes red blood cell transfusion for anemia . The immunomodulatory agents (imids) ...

    Research Article last updated 10/01/2012 - 10:04am.

  3. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    ... Journal Title:  Blood Primary Author:  ... the efficacy and safety of lenalidomide in 205 RBC transfusion-dependent patients with IPSS Low-/Intermediate-1-risk del5q31 ...

    Research Article last updated 07/28/2014 - 9:04am.

  4. Blood stream infection after stem cell transplantation in children with idiopathic aplastic anemia

    ... Journal Title:  Biol Blood Marrow Transplant Primary ... transplantation from unrelated donors, frequent blood transfusion before transplantation, major or major+minor mismatch of ABO ...

    Research Article last updated 04/23/2014 - 10:34am.

  5. Personalized medicine for MDS

    ... patients into “lower-risk” disease, where improvement in blood counts is the main goal of therapy, and “higher-risk” disease, where ... agents (ESAs) as a single agent reduces transfusion dependence in about 50% of lower-risk MDS patients.  However, no ...

    Research Review last updated 05/02/2016 - 9:44am.

  6. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response

    ... Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with ... The study cohort consisted of patients with new-onset transfusion dependence (TD). All patients received an ESA at least once during ...

    Research Article last updated 05/26/2015 - 11:49am.

  7. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... Overall Response (complete or partial remission, red blood cell [RBC] or platelet transfusion independence [TI], or hematologic improvement, (IWG 2006) was ...

    Research Article last updated 12/09/2015 - 8:56am.

  8. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.

    ... Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and ... achieved long-term packed red blood cell PRBC transfusion independence , and all PRCA responders achieved long-term ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk ... of these patients had an ongoing requirement for red blood cell transfusions despite previous treatment with recombinant ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... Journal Title:  Blood Primary Author:  ... six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by CH50 ≤10% of ...

    Research Article last updated 01/20/2015 - 2:28pm.